Reaction
Recall Phenomenon reporting signals
As of the last recalculation, Recall Phenomenon appears in 825 FAERS reports alongside 25 co-occurring drug terms. The strongest observed disproportionality signal is GEMCITABINE HYDROCHLORIDE (PRR 79.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Gemcitabine Hydrochloride | 139 | 79.3 | 79.5 |
| Gemcitabine | 101 | 73.6 | 73.8 |
| Docetaxel Anhydrous | 117 | 50.9 | 51.0 |
| Docetaxel | 117 | 50.9 | 51.0 |
| Pertuzumab | 35 | 33.9 | 33.9 |
| Trastuzumab | 81 | 32.9 | 32.9 |
| Gefitinib | 10 | 28.3 | 28.3 |
| Ifosfamide | 23 | 27.8 | 27.8 |
| Cisplatin | 67 | 23.5 | 23.5 |
| Pemetrexed Disodium | 31 | 21.3 | 21.3 |
| Vemurafenib | 10 | 21.2 | 21.3 |
| Paclitaxel (Aibumin-Bound) | 64 | 21.2 | 21.2 |
| Ado-Trastuzumab Emtansine | 7 | 21.1 | 21.1 |
| Carboplatin | 89 | 19.7 | 19.7 |
| Fluorouracil | 55 | 19.1 | 19.2 |
| Paclitaxel | 69 | 19.1 | 19.1 |
| Fluorouracil Cream, 0.5% | 54 | 19.0 | 19.1 |
| Capecitabine | 61 | 18.1 | 18.1 |
| Levodopa | 8 | 16.9 | 16.9 |
| Oxaliplatin | 42 | 15.0 | 15.0 |
| Rotigotine | 8 | 14.1 | 14.1 |
| Pazopanib Hydrochloride | 13 | 12.3 | 12.3 |
| Abemaciclib | 9 | 11.5 | 11.5 |
| Etoposide | 32 | 11.4 | 11.4 |
| Cetuximab | 11 | 9.0 | 9.0 |